Accent Therapeutics: Accent Therapeutics starts dosing in trial of KIF18A inhibitor for solid tumours

Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member 18A inhibitor. The post Accent Therapeutics starts dosing in trial of KIF18A inhibitor for solid tumours appeared first on Clinical Trials Arena.